These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 9746454)

  • 1. Treatment of obsessive-compulsive cutting behavior with naltrexone.
    Bystritsky A; Strausser BP
    J Clin Psychiatry; 1996 Sep; 57(9):423-4. PubMed ID: 9746454
    [No Abstract]   [Full Text] [Related]  

  • 2. Atypical anorexia in a male patient accompanied by strong obsessive-compulsive symptoms successfully treated with naltrexone.
    Gade K; Häussinger C; Bandelow B
    Pharmacopsychiatry; 2009 Jul; 42(4):164-5. PubMed ID: 19585396
    [No Abstract]   [Full Text] [Related]  

  • 3. Naltrexone treatment of self-injurious behavior.
    Godart NT; Agman G; Perdereau F; Jeammet P
    J Am Acad Child Adolesc Psychiatry; 2000 Sep; 39(9):1076-8. PubMed ID: 10986803
    [No Abstract]   [Full Text] [Related]  

  • 4. Use of a narcotic antagonist (nalmefene) to suppress self-mutilative behavior in a stallion.
    Dodman NH; Shuster L; Court MH; Patel J
    J Am Vet Med Assoc; 1988 Jun; 192(11):1585-6. PubMed ID: 3410777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effects of naltrexone on automutilation behavior in autistic psychosis].
    Decocq G; Kandelaft N; Compagnon M
    Presse Med; 1996 Feb; 25(7):305. PubMed ID: 8685173
    [No Abstract]   [Full Text] [Related]  

  • 6. Naltrexone for severe self-harm behavior: a case report.
    Agarwal LJ; Berger CE; Gill L
    Am J Psychiatry; 2011 Apr; 168(4):437-8. PubMed ID: 21474600
    [No Abstract]   [Full Text] [Related]  

  • 7. Naltrexone for the treatment of trichotillomania: a case report.
    Carrion VG
    J Clin Psychopharmacol; 1995 Dec; 15(6):444-5. PubMed ID: 8748437
    [No Abstract]   [Full Text] [Related]  

  • 8. Factor structure and predictive validity of the Obsessive Compulsive Drinking Scale.
    Roberts JS; Anton RF; Latham PK; Moak DH
    Alcohol Clin Exp Res; 1999 Sep; 23(9):1484-91. PubMed ID: 10512314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of narcotic antagonists on self-injurious behavior: a single case study.
    Bernstein GA; Hughes JR; Mitchell JE; Thompson T
    J Am Acad Child Adolesc Psychiatry; 1987 Nov; 26(6):886-9. PubMed ID: 3429408
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical uses of naltrexone: a review of the evidence.
    Modesto-Lowe V; Van Kirk J
    Exp Clin Psychopharmacol; 2002 Aug; 10(3):213-27. PubMed ID: 12233982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Obsessive disorder with self-mutilation: a subgroup responsive to pharmacotherapy.
    Primeau F; Fontaine R
    Can J Psychiatry; 1987 Nov; 32(8):699-701. PubMed ID: 3500773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding and treating kleptomania: new models and new treatments.
    Grant JE
    Isr J Psychiatry Relat Sci; 2006; 43(2):81-7. PubMed ID: 16910369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A possible new treatment approach to obsessive-compulsive disorder.
    Warneke L
    Can J Psychiatry; 1997 Aug; 42(6):667-8. PubMed ID: 9288436
    [No Abstract]   [Full Text] [Related]  

  • 14. A double-blind, placebo-controlled study of the opiate antagonist, naltrexone, in the treatment of kleptomania.
    Grant JE; Kim SW; Odlaug BL
    Biol Psychiatry; 2009 Apr; 65(7):600-6. PubMed ID: 19217077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. More on self mutilation and obsessive compulsive disorder.
    Hollander E; Papp L; Campeas R; DeCaria C; Liebowitz MR
    Can J Psychiatry; 1988 Oct; 33(7):675. PubMed ID: 3058294
    [No Abstract]   [Full Text] [Related]  

  • 16. Naltrexone decreases self-injurious behavior.
    Herman BH; Hammock MK; Arthur-Smith A; Egan J; Chatoor I; Werner A; Zelnik N
    Ann Neurol; 1987 Oct; 22(4):550-2. PubMed ID: 3481242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Naltrexone in adults with intellectual disability improves compulsive and dissocial disorders: a case report.
    Orihuela-Flores M; Deriaz N; Carminati GG
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Aug; 34(6):1137-8. PubMed ID: 20460140
    [No Abstract]   [Full Text] [Related]  

  • 18. Anti-androgenic treatment of obsessive-compulsive disorder: an open-label clinical trial of the long-acting gonadotropin-releasing hormone analogue triptorelin.
    Eriksson T
    Int Clin Psychopharmacol; 2007 Jan; 22(1):57-61. PubMed ID: 17159461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term treatment of post-traumatic stress disorder with naltrexone: an open-label preliminary study.
    Lubin G; Weizman A; Shmushkevitz M; Valevski A
    Hum Psychopharmacol; 2002 Jun; 17(4):181-5. PubMed ID: 12404685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of efficacy of low doses of quetiapine addition in refractory obsessive-compulsive disorder.
    Sevincok L; Topuz A
    J Clin Psychopharmacol; 2003 Oct; 23(5):448-50. PubMed ID: 14520120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.